Demand Fundamental	Value	Score	Rating
Qtr/Qtr Revenue Growth	Members Only
Qtr/Qtr Earnings Growth	Members Only
Year/Year Revenue Growth	Members Only
Year/Year Earnings Growth	Members Only
Multi-Year Revenue Growth	Members Only
Multi-Year Earnings Growth	Members Only
Relative PE Ranking	Members Only
Return on Equity	Members Only
Yield	Members Only
Institutional Holding	Members Only
Stock Price	Members Only
Relative Fundamental Ranking	Members Only
Total Score	Members Only

Demand Technical	Value	Score	Rating
Recommended Condition	Members Only
Trading Zone	Members Only
Average Trading Volume	Members Only
Industry Bull/Bear Condition	Members Only
Sector Bull/Bear Condition	Members Only
Current Signal Start Date	Members Only
Total Score	Members Only

Allos Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of anti-cancer therapeutics. The company provides FOLOTYN (pralatrexate injection), a folate inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma. It also offers FOLOTYN as a single agent and in combination therapy regimens in various hematologic malignancies and solid tumor indications, including breast and bladder cancer. The company sells its FOLOTYN product to pharmaceutical wholesale distributors who then resell it to patients' respective health care providers. It has strategic collaboration agreement with Mundipharma International Corporation Limited for the co-development of FOLOTYN (pralatrexate injection). The company was formerly known as HemoTech Sciences, Inc. and changed its name to Allos Therapeutics, Inc. in October 1994. Allos Therapeutics, Inc. was founded in 1992 and is headquartered in Westminster, Colorado.